VENTAC PARTNERS IS A DEDICATED LIFE SCIENCE CONSULTING FIRM WITH OFFICES IN EUROPE, USA AND ASIA.

Ventac Partners has a strong track record in founding new innovative companies, strategic and operational market and product analysis, intellectual property development, fund raising, licensing, M&A and strategy consulting.

All partners are experienced executives from pharma, biotech and medtech companies, and preclinical, clinical and regulatory, legal and intellectual property experts with extensive backgrounds in successfully starting, growing and expanding international life science companies.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Latest News
January, 2011 | Avexxin closes series A financing round enabling the company to take its lead compound forward through clinical trial phase I/IIa.

December, 2011 | Mikael Oerum appointed Member of the Scientific Advisory Board of Virginia Bioinformatics Institute at Virginia Tech, USA

November, 2011 | APIM Therapeutics secures follow up seed funding from Birk Venture, Ro Invest and Sarsia Seed with the support of Ventac Partners.

October, 2011 | Ventac Partners completes a strategic business and market analysis for HUNT Biosciences, the commercial arm of the largest population based biobank in Norway.

More News

Announcements
APIM Therapeutics
APIM Therapeutics AS, a company developing an innovative drug approach aiming at increasing the therapeutic index of a wide range of marketed chemotherapeutics, is currently seeking series A funding to further advance its compound portfolio.

Download BRIEF